Sclerosing cholangitis and intracranial lymphoma in a child with classical Wiskott–Aldrich syndrome

Pediatric Blood and Cancer

Volumn 64, Issue 1, 2017, Pages 106-109

  Vignesh, Pandiarajan ^a   Suri, Deepti ^a   Rawat, Amit ^a   Lau, Yu Lung ^b   Bhatia, Anmol ^a   Das, Ashim ^a   Srinivasan, Anirudh ^a   Dhandapani, Sivashanmugam ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CNS lymphoma; primary sclerosing cholangitis; Wiskott Aldrich syndrome

Indexed keywords

ALKALINE PHOSPHATASE; CD20 ANTIGEN; CEFOTAXIME; COTRIMOXAZOLE; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PREDNISOLONE; URSODEOXYCHOLIC ACID; WISKOTT ALDRICH SYNDROME PROTEIN;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BILE DUCT DILATATION; BRAIN LYMPHOMA; CANCER GRADING; CASE REPORT; CHILD; CHILDHOOD CANCER; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; ECZEMA; ERYTHROCYTE TRANSFUSION; FOLLOW UP; FRONTAL LOBE; GENETIC ANALYSIS; GENOTYPE; HEADACHE; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LEUKOCYTOCLASTIC VASCULITIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; MELENA; MOLLUSCUM CONTAGIOSUM; NEUROIMAGING; NONHODGKIN LYMPHOMA; PALLIATIVE THERAPY; PNEUMONIA; PRESCHOOL CHILD; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SUBSTITUTION THERAPY; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; THROMBOCYTOPENIA; WISKOTT ALDRICH SYNDROME; ADOLESCENT; ANEMIA, HEMOLYTIC, AUTOIMMUNE; BRAIN NEOPLASMS; CHOLANGITIS, SCLEROSING; COMPLICATION; GENETICS; LYMPHOMA, NON-HODGKIN; MUTATION; PATHOLOGY; PROGNOSIS;

ADOLESCENT; ANEMIA, HEMOLYTIC, AUTOIMMUNE; BRAIN NEOPLASMS; CHOLANGITIS, SCLEROSING; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MUTATION; PROGNOSIS; THROMBOCYTOPENIA; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN;

EID: 84983526959     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.26196     Document Type: Article

References (19)

1. Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott–Aldrich Syndrome Protein (WASP): Hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 2004;104(13):4010–4019.
2. Akman IO, Ostrov BE, Neudorf S. Autoimmune manifestations of the Wiskott–Aldrich syndrome. Semin Arthritis Rheum. 1998;27(4):218–225.
3. Chinen J, Notarangelo LD, Shearer WT. Advances in basic and clinical immunology in 2014. J Allergy Clin Immunol. 2015;135(5):1132–1141.
4. Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103(2):456–464.
5. Adriani M, Aoki J, Horai R, et al. Impaired in vitro regulatory T cell function associated with Wiskott–Aldrich syndrome. Clin Immunol. 2007;124(1):41–48.
6. Recher M, Burns SO, de la Fuente MA, et al. B cell-intrinsic deficiency of the Wiskott–Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood. 2012;119(12):2819–2828.
7. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott–Aldrich syndrome. J Pediatr. 1994;125(6 Pt 1):876–885.
8. De Meester J, Calvez R, Valitutti S, Dupré L. The Wiskott–Aldrich syndrome protein regulates CTL cytotoxicity and is required for efficient killing of B cell lymphoma targets. J Leukoc Biol. 2010;88(5):1031–1040.
9. Wengler GS, Notarangelo LD, Berardelli S, et al. High prevalence of nonsense, frame shift, and splice-site mutations in 16 patients with full-blown Wiskott–Aldrich syndrome. Blood. 1995;86(10):3648–3654.
10. Greer WL, Shehabeldin A, Schulman J, Junker A, Siminovitch KA. Identification of WASP mutations, mutation hotspots and genotype–phenotype disparities in 24 patients with the Wiskott–Aldrich syndrome. Hum Genet. 1996;98(6):685–690.
11. El-Hakeh J, Rosenzweig S, Oleastro M, et al. Wiskott–Aldrich syndrome in Argentina: 17 unique, including nine novel, mutations. Hum Mutat. 2002;19(2):186–187.
12. Lutskiy MI, Rosen FS, Remold-O'Donnell E. Genotype–proteotype linkage in the Wiskott–Aldrich syndrome. J Immunol. 2005;175(2):1329–1336.
13. Yimam KK, Bowlus CL. Diagnosis and classification of primary sclerosing cholangitis. Autoimmun Rev. 2014;13(4–5):445–450.
14. Mahdavinia M, Mirsaeidi M, Bishehsari F, McGrath K. Primary sclerosing cholangitis in common variable immune deficiency. Allergol Int. 2015;64(2):187–189.
15. Girard M, Franchi-Abella S, Lacaille F, Debray D. Specificities of sclerosing cholangitis in childhood. Clin Res Hepatol Gastroenterol. 2012;36(6):530–535.
16. Kahn K, Sharp H, Hunter D, Kerzner B, Jessurun J, Blaese M. Primary sclerosing cholangitis in Wiskott–Aldrich syndrome. J Pediatr Gastroenterol Nutr. 2001;32(1):95–99.
17. Cotelingam JD, Witebsky FG, Hsu SM, Blaese RM, Jaffe ES. Malignant lymphoma in patients with the Wiskott–Aldrich syndrome. Cancer Invest. 1985;3(6):515–522.
18. Coccia P, Mastrangelo S, Ruggiero A, et al. Treatment of pharyngeal non-Hodgkin lymphoma in a patient with Wiskott–Aldrich syndrome. Pediatr Blood Cancer. 2012;59(2):318–389.
19. Bhagavathi S, Wilson JD. Primary central nervous system lymphoma. Arch Pathol Lab Med. 2008;132(11):1830–1834.